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Ascorbic acid, at physiological concentrations, can scavenge the myeloperoxidase-derived oxi ant hypo- 
chlorous acid at rates sufficient to protect a,-antiprotease against inactivation by this molecule. The rapid 
depletion of ascdrbic acid at sites of inflammation, asin the inflamed rheumatoid joint, may therefore facili- 
tate proteolytic damage. 
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1. INTRODUCTION 
Ascorbic acid (vitamin C) has complex effects 
on systems generating oxygen free radicals. For ex- 
ample, ascorbic acid reacts quickly with superox- 
ide radical, 02, and with hydroxyl radical, ‘OH 
[ 1,2] and its ability to scavenge these species may 
be biologically important in lung [3], at sites of in- 
flammation [4] and in chloroplasts IS]. However, 
mixtures of ascorbic acid and iron or copper salts 
can also generate damaging radical species, in- 
cluding ‘OH (6-81. Neutrophils are rich in ascor- 
bic acid, much of which becomes oxidized during 
activation of the respiratory burst [9]. Activated 
neutrophils also oxidize extracellular ascorbic acid, 
a reaction that seems to be largely mediated by 02 
[4]. In the synovial fluid from inflamed 
rheumatoid joints, both the total ascorbic acid 
(reduced plus oxidized) and the [ascor- 
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bate]/[dehydroascorbate] ratio are markedly 
decreased [lo, 111. Even in rheumatoid sera, these 
values are sub-normal flO,ll]. A lowered concen- 
tration of ascorbic acid will minimize O;-scaveng- 
ing antioxidant protection in the inflamed 
rheumatoid joint [ 101, 
Activated neutrophils release the enzyme 
myeloperoxidase, which uses some of the Hz02 
produced during the respiratory burst to oxidise 
Cl- into a powerful oxidant that has been iden- 
tified as h~ochlorous acid, HOC1 f12-141. 
Hypochlorous acid oxidizes a wide range of 
biomolecules, but its most important cellular 
target is probably the ai-antiprotease protein, 
which protects tissues against proteases such as 
elastase, also released from activated neutrophils 
[ 121. Ascorbic acid has already been suggested to 
react with HOC1 [4,14], but it is important to know 
if this reaction is swift enough at physiological 
ascorbate concentrations (normal serum and 
synovial fluid concentrations are in the range 
40-141 pM [iO,11,15,16]) to protect important 
biological targets such as cui-antiprotease. In the 
present paper, this point has been investigated. 
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2. MATERIALS AND METHODS 
2.1. Reagents 
6.2 with dilute H2SO4, and its concentration deter- 
mined as in [ 171. The HPLC equipment used is 
described in [ 18-201. 
ai-Antiprotease (type A9024) was from Sigma. 
Other reagents, including porcine pancreatic 
elastase, NaOCl and ascorbic acid, were from 
BDH. 
3. RESULTS 
2.2. Assays 
Elastase and cui-antiprotease were assayed essen- 
tially as described in [17,18]; full details are given 
in the legend to table 1. HOC1 was obtained 
immediately before use by adjusting NaOCl to pH 
Table 1 (column A) shows that ascorbic acid had 
no action on elastase activity at the concentrations 
tested. ui-Antiprotease inhibits elastase, and its 
ability to do this was also unaffected by ascorbic 
acid (column B). The concentration of &i-anti- 
protease that could inhibit elastase by about 97% 
was chosen for these experiments, but very similar 
results were obtained at other elastase : al-anti- 
protease ratios. 
Table 1 
Effect of ascorbic acid on elastase, its inhibition by 
err-antiprotease and inactivation of err-antiprotease by 
HOC1 
*,,,~a.032 T 
Final concentration of Elastase activity 
ascorbic acid in (Or0 maximum rate) 
reaction system A 
01M) A B c D 
0 100 3 99 98 
5 100 3 90 42 
10 99 2 81 8 
21 101 4 65 3 
42 98 3 34 2 
83 103 3 15 3 
167 100 2 6 2 
cYr-Antiprotease (final concentration 0.5 mg/ml) was 
mixed with the final concentration of ascorbic acid 
stated plus HOC1 (30 pM final concentration) in buffer 
at pH 7.4 [17,18] and incubated at 25°C for 60 min 
(reaction system A). 3 ml of buffer [17,18] are then 
added, plus elastase. After further incubation for 30 min 
the elastase activity remaining is assayed as the rise in 
absorbance at 410 nm [17,18]. Results are expressed as 
the % of maximum elastase activity (A4re 0.0599.min-’ 
corresponds to 100%). Column A, both HOC1 and 
antiprotease omitted from reaction system A, so that 
any effect of ascorbic acid on the elastase activity can be 
tested. Column B, HOC1 omitted from reaction system 
A, so that any effect of ascqrbic acid on the ability of 
ar-antiprotease to inhibit elastase can be tested. Column 
C, complete reaction mixture as above. Column D, as 
for C, but HOC1 and ascorbic acid pre-incubated for 
5 min before adding cYr-antiprotease, then incubation 
for a further 60 min before adding elastase and buffer as 
J- 
a 
+I+ 
o- 8 
MIN 
Fig. 1. HPLC evidence for reaction of ascorbic acid with 
HOCI. HPLC was carried out on a pre-packed 
4.6 mm x 25 cm Anachem S5 ODS-2 column with an 
Anachem S5 ODS-2 guard column [18-201. The mobile 
phase was 90% (v/v) 30 mM sodium titrate/27.7 mM 
sodium acetate buffer, pH 7.4, 10% (v/v) methanol at 
a flow rate of 1.0 ml. min-‘, continuously sparged with 
helium. Ascorbic acid was detected by its absorbance at 
265 nm. 27 pM ascorbic acid in 20 mM KHzPOd-KOH 
buffer, pH 7.4, was incubated with 25pM HOC1 for 
20 min at 37°C. Peak A, control incubation (no HOC1 
added); peak B, HOC1 present. The ascorbic acid 
concentration decreased to 17 ,uM. If 50 pM HOC1 was 
present, [ascorbic acid] decreased to 5 PM and 100 pM 
HOC1 decreased [ascorbic acid] to 1.5 CM. No oxidation 
products of ascorbic acid were observed with the UV 
described above detector. i, injection spike. 
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If the ~~-antiprotease is exposed to HOC1 before 
adding elastase, its ability to inhibit is lost (column 
C, first row) and elastase activity is high, The 
HOC1 concentration chosen is within the range of 
concentrations likely to be produced adjacent to 
myeloperoxidase in vivo [ 13,14,22]. Column C 
also shows the effect of including ascorbic acid in 
the reaction mixture with HOC1 and al-anti- 
protease. It seems that ascorbic acid, at phys- 
iologically relevant concentrations, is able to 
protect cYt-antiprotease against inactivation by 
HOCl, so that it can still inhibit elastase. This pro- 
tective effect of ascorbic acid is greatly enhanced 
by pre-incubating it with HOC1 before adding the 
cul-antiprotease, suggesting that ascorbic acid is 
acting by scavenging HOC1 (column D). On the 
other hand, ascorbic acid cannot restore the activi- 
ty of Al-~tiprotease after HOC1 treatment (not 
shown). 
In order to confirm a reaction of ascorbic acid 
with HOCl, HPLC analysis was used. Fig.1 shows 
that incubation of ascorbic acid with HOC1 at pH 
7.4 caused its disappearance. 
4. DISCUSSION 
The results in the present paper confirm 
previous suggestions that HOC1 reacts with ascor- 
bic acid 14,141. More importantly, they show that 
this effect is biologi~~ly signifi~~t, in that the 
concentrations of ascorbic acid normally present in 
serum and synovial fluid [10,11,15,16] can offer 
protection to the important biological target 
tui-antiprotease against inactivation by HOC1 pro- 
duced by myeloperoxidase [ 121. In serum, albumin 
is an effective HOC1 scavenger [17], but albumin 
concentrations in synovial fluid are much lower 
than in serum [21] and so the protective effect of 
ascorbic acid against HOC1 produced by 
myeloperoxidase may well be very significant at 
this site. The rapid depletion of ascorbic acid at 
sites of intimation, as in rheumatoid arthritis, 
by reaction with 02 [4] and ‘OH [ 1,7], will thus be 
expected to lead to increased protease activity con- 
sequent upon al-antiprotease inactivation, and an 
exacerbation of damage. 
We thank the Arthritis and Rheumatism Council 
for research support. B.H. is a Lister Institute 
Research Fellow. 
REFERENCES 
111 
121 
131 
[41 
PI 
161 
r71 
181 
I91 
WI 
1111 
WI 
I131 
1141 
ml 
WI 
[I71 
WI 
WI 
PO1 
1211 
WI 
Anbar, M. and Neta, P. (1967) Int. J. Appl. 
Radiat. Isot. 18, 493-523. 
Nishikimi, M. (1975) Biochem. Biophys. Res. 
Commun. 63, 463-468. 
Grad, I.D., Forman, H.J. and Fisher, A.B. (1980) 
J. Lab. Clin. Med. 96, 673-681. 
Hemill, H., Roberts, P. and Wikstrbm, M. (1984) 
FEBS Lett. 178, 25-30. 
Halliwell, B. (1984) Chloroplast Metabolism, 
Clarendon Press, Oxford. 
Winterbourn, C.C. (1979) Biochem. J. 182, 
625-628. 
Rowley, D.A. and HaIliwell, B. (1983) Clin. Sci. 
64, 649-653. 
Czapski, G. and Goldstein, S. (1986) Free Radical 
Res. Commun. 1, 157-161. 
Winterbourn, C.C. and Vissers, M.C.M. (1983) 
Biochii. Biophys. Acta 763, 175-179. 
Blake, D.R., Hail, N.D., Treby, D.A., Halliwell, 
B. and Gutteridge, J.M.C. (1981) Clin. Sci. 61, 
483-486. 
Lunec, J. and Blake, D.R. (1985) Free Radical Res. 
Commun. 1, 31-39. 
Weiss, S.J. (1986) Acta Physiol. Stand. ~~~~1.548, 
9-37. 
Albrich, J.M., McCarthy, C.A. and Hurst, J.K. 
(1981) Proc. Natl. Acad. Sci. USA 78, 210-214. 
Winterbourn, C.C. (1985) Biochim. Biophys. Acta 
840, 204-210. 
Koch, P., Sidioi, M. and Tonks, D.B. (1980) Clin. 
B&hem. 13, 73-77. 
Samyn, W. (1983) Clin. Chim. Acta 133, I I l-117. 
Wasil, M., Halliwell, B., Hutchison, D.C.S. and 
Baum, H. (1987) Biochem. J., in press. 
Grootveld, M., Halliwell, B. and Moorhouse, C.P. 
(1987) Free Radical Res. Commun., in press. 
Grootveld, M. and Halliwell, B. (1986) Biochem. J, 
237, 499-504. 
Grootveld, M. and Halliwell, B. (1986) Free 
Radical Res. Commun. 1, 243-250. 
Gutteridge, J.M.C. (1986) Biochim. Biophys. Acta 
869, 119-127. 
Kalyanaraman, B. and Sohnle, P.G. (1985) J. Clin. 
Invest. 75, 1618-1622. 
17 
